Replies to post #137803 on Biotech Values

[DewDiligence]

It's possible that the developers of all-oral combinations are starting to move away from RGT in order to avoid this potential pricing dilemma but I think another explanation may be that they expect patients that could benefit from shorter LoT to be gone by 2015 and so they don't want to develop something for a vanishing market.

Agreed. The cynical interpretation for the discontinuation of RGT presented in #msg-72495616 was intended to be one explanation, not the only explanation.